Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant
A new Tel Aviv University study pinpoints the inverse correlation between a known oncogene — a gene that promotes the development of cancer — and the expression of an oncosuppressor microRNA as the reason for extended pancreatic cancer survival. The study may serve as a basis for the development of an effective cocktail of drugs for this deadly disease and other cancers.
The study, which was published in Nature Communications, was led by Prof. Ronit Satchi-Fainaro, Chair of the Department of Physiology and Pharmacology at TAU’s Sackler Faculty of Medicine, and conducted by Hadas Gibori and Dr. Shay Eliyahu, both of Prof. Satchi-Fainaro’s multidisciplinary laboratory, in collaboration with Prof. Eytan Ruppin of TAU’s Computer Science Department and the University of Maryland and Prof. Iris Barshack and Dr. Talia Golanof Chaim Sheba Medical Center, Tel Hashomer.
Pancreatic cancer is among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients die within just a year of diagnosis. “Despite all the treatments afforded by modern medicine, some 75% of all pancreatic cancer patients die within 12 months of diagnosis, including many who die within just a few months,” Prof. Satchi-Fainaro says.
“But around seven percent of those diagnosed will survive more than five years. We sought to examine what distinguishes the survivors from the rest of the patients,” Prof. Satchi-Fainaro continues. “We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy.”
Calling a nano-taxi
The research team examined pancreatic cancer cells and discovered an inverse correlation between the signatures of miR-34a, a tumor suppressant, and PLK1, a known oncogene. The levels of miR-34a were low in pancreatic cancer mouse models, while the levels of the oncogene were high. This correlation made sense for such an aggressive cancer. But the team needed to see if the same was true in humans.
The scientists performed RNA profiling and analysis of samples taken from pancreatic cancer patients. The molecular profiling revealed the same genomic pattern found earlier in mouse models of pancreatic cancer.
The scientists then devised a novel nanoparticle that selectively delivers genetic material to a tumor and prevents side effects in surrounding healthy tissues.
“We designed a nanocarrier to deliver two passengers: (1) miR-34a, which degrades hundreds of oncogenes; and (2) a PLK1 small interfering RNA (siRNA), that silences a single gene,” Prof. Satchi-Fainaro says. “These were delivered directly to the tumor site to change the molecular signature of the cancer cells, rendering the tumor dormant or eradicating it altogether.
“The nanoparticle is like a taxi carrying two important passengers,” Prof. Satchi-Fainaro continues. “Many oncology protocols are cocktails, but the drugs usually do not reach the tumor at the same time. But our ‘taxi’ kept the ‘passengers’ — and the rest of the body — safe the whole way, targeting only the tumor tissue. Once it ‘parked,’ an enzyme present in pancreatic cancer caused the carrier to biodegrade, allowing the therapeutic cargo to be released at the correct address — the tumor cells.”
Improving the odds
To validate their findings, the scientists injected the novel nanoparticles into pancreatic tumor-bearing mice and observed that by balancing these two targets — bringing them to a normal level by increasing their expression or blocking the gene responsible for their expression — they significantly prolonged the survival of the mice.
“This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general,” according to Prof. Satchi-Fainaro.
The Latest on: Pancreatic cancer
- Alex Trebek, who is battling pancreatic cancer, sends ‘Jeopardy!’ fans a hopeful message on April 17, 2019 at 10:01 pm
Alex Trebek signed off following the final day of taping for the 35th year of “Jeopardy!”, and he told fans of the popular game show that he planned to return later this year for another season of ... […]
- Achilles’ heel of pancreatic cancer may lead to improved patient treatment on April 17, 2019 at 9:14 pm
Scientists may have discovered the “Achilles’ heel” of pancreatic cancer – a condition which is notoriously difficult to treat. Researchers believe a protein called leukaemia inhibitory factor (LIF) ... […]
- Alex Trebek says he's 'feeling good' amid cancer battle, plans to host 'Jeopardy!' season 36 on April 17, 2019 at 6:54 pm
FOX NEWS - Cancer won't slow down "Jeopardy!" host Alex Trebek. He's filmed 50 episodes since being diagnosed with pancreatic cancer in March and in a new video update to fans on Wednesday, said he's ... […]
- WATCH: ‘Jeopardy’ host Alex Trebek gives update on his progress after pancreatic cancer diagnosis. ‘I’m touched beyond words.’ on April 17, 2019 at 6:37 pm
When Alex Trebek announced in March that he had been diagnosed with stage 4 pancreatic cancer, “Jeopardy!" fans rallied to support him. Trebek vowed to stay on the job, even as he sought treatment — ... […]
- Dr. Tempero on Role of Molecular Profiling in Pancreatic Cancer on April 17, 2019 at 3:02 pm
Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor ... […]
- Some Dying Cancer Patients Still Receive Active Therapies on April 17, 2019 at 1:30 pm
Older patients with lung cancer were less likely to receive radiotherapy. The odds of receiving chemotherapy and radiotherapy were also lower for lung and pancreatic cancer patients who had higher ... […]
- New study targets Achilles' heel of pancreatic cancer, with promising results on April 17, 2019 at 1:00 pm
Advanced pancreatic cancer is often symptomless, leading to late diagnosis only after metastases have spread throughout the body. Now, researchers have uncovered the role of a signaling protein, ... […]
- 'Mami's Message' to raise money for pancreatic cancer research on April 17, 2019 at 11:34 am
Natalia Piferrer and her mother used to spend every birthday going out to dinner and making wishes on candles. This year, Piferrer will spend her mother’s birthday making with another wish: to raise ... […]
- Key protein a possible new target in the treatment of pancreatic cancer on April 17, 2019 at 10:21 am
WOODBURY, N.Y., April 17, 2019 -- Pancreatic cancer can be difficult to treat and often responds poorly to chemotherapy due to the presence of tumor cells located within the dense protective tissue, ... […]
- Neoadjuvant Strategy Improves Survival in Pancreatic Cancer Resection on April 15, 2019 at 12:42 pm
Researchers sought to identify predictive factors associated with morbidity, mortality, and survival outcomes in patients with BR or LA PDAC who undergo TNT prior to surgical resection. Pancreatic ... […]
via Google News and Bing News